Core Insights - Inspira Technologies is planning a strategic expansion into liquid biopsy diagnostics, aiming to preserve shareholder value while enabling future dividend distributions from its core technologies [1][2] - The proposed acquisition of a liquid biopsy platform is seen as a significant value inflection point, enhancing Inspira's capabilities in blood-based diagnostics and real-time monitoring [2][3] Company Operations - Inspira has developed the HYLA™ blood sensor platform, achieving 95% to 99% accuracy in clinical testing, and has established a dedicated blood diagnostics laboratory to support its expansion into adjacent diagnostic applications [2][3] - The company’s FDA-cleared INSPIRA™ ART100 system is currently deployed in leading U.S. hospitals, contributing to a growing commercial pipeline expected to generate revenue in 2026 [7][8] Liquid Biopsy Technology - The targeted liquid biopsy platform analyzes intact circulating tumor cells (CTCs) from blood samples, providing a more direct view of tumor characteristics over time, which could significantly improve current diagnostic practices [3][4] - Initially focusing on breast cancer, the platform is designed for routine clinical use and has shown high concordance with traditional tissue biopsies, with potential adaptability across various solid tumor indications [5][6] Transaction Structure - The acquisition is structured to allow Inspira to acquire the liquid biopsy business in exchange for up to 40% of its issued and outstanding share capital, while ensuring existing shareholders benefit from the value generated by the core respiratory business through a Contingent Value Rights (CVR) framework [13] - A concurrent equity investment of $15 million is expected to support the integration of the liquid biopsy platform and the advancement of Inspira's existing operations, with a pre-money valuation of $180 million [13][9]

Core Viewpoint - Inspira Technologies is planning a strategic expansion into liquid biopsy diagnostics, aiming to preserve shareholder value while enabling future dividend distributions from its core respiratory and life-support technologies [1][2]. Company Strategy - The proposed acquisition of a liquid biopsy platform is seen as a significant value inflection point, enhancing Inspira's diagnostics capabilities with long-term potential [2]. - The transaction is structured to optimize value allocation between the new platform and Inspira's existing respiratory business through a Contingent Value Rights (CVR) framework [2][12]. - The acquisition is positioned as a natural extension of Inspira's competencies in blood-based diagnostics and real-time monitoring, leveraging its proprietary HYLA™ blood sensor platform [2][7]. Liquid Biopsy Technology - The targeted liquid biopsy platform analyzes intact circulating tumor cells (CTCs) from blood samples, offering a more direct view of tumor characteristics over time [3]. - Initial focus is on breast cancer, where changes in biomarkers can significantly impact treatment options, enabling minimally invasive testing to monitor tumor evolution [4][5]. - The technology is designed for routine clinical use and has shown high concordance with traditional tissue biopsy in preliminary validations, with plans for adaptability across various solid tumor indications [5][6]. Current Operations - Inspira's existing operations in respiratory care and life-support are advancing, with the FDA-cleared INSPIRA™ ART100 system deployed in leading U.S. hospitals [7]. - The company is expected to generate revenue from previously announced purchase orders during 2026 [7]. Financial Aspects - The proposed equity investment of up to $15 million is intended to support ongoing operations and further development of existing platforms, with $12 million specifically allocated for this purpose [8][12]. - The acquisition structure allows Inspira to acquire the liquid biopsy business in exchange for up to 40% of its issued share capital, ensuring economic benefits for current shareholders through the CVR framework [12]. Transaction Timeline - The acquisition and equity investment are expected to close concurrently, pending customary conditions, including shareholder and regulatory approvals, with a target for execution of definitive agreements within approximately four weeks from January 5, 2026 [12].